Novel Sulfonylhydrazones With Sulfonate Ester Framework: Promising Dual Inhibitors of AChE and hCAs
Biotechnology and Applied Biochemistry · 2025-12 · 72 (6) · 1752-1762
DOI: 10.1002/bab.2780 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology and Applied Biochemistry, online erschienen am 04.05.2025. Verfasst von Cansu Öztürk und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Science, Department of Chemistry, Atatürk University, Erzurum, Turkey. Hauptthemen laut MEDLINE: Hydrazones, Cholinesterase Inhibitors, Carbonic Anhydrase Inhibitors, Acetylcholinesterase. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that affects millions of individuals worldwide. Treatment strategies for AD vary depending on cognitive and behavioral symptoms, with cholinergic replacement therapy using acetylcholinesterase (AChE) inhibitors being one of the primary approaches. Recent studies have also identified human carbonic anhydrases (hCAs) as significant therapeutic targets for AD, offering new opportunities for the development of innovative treatments. Carbonic anhydrase inhibitors have been shown to prevent early mitochondrial damage and inhibit H 2 O 2 production, thereby reducing amyloid plaque formation. Building on the promising potential of hydrazones particularly sulfonyl hydrazones as anticholinesterase agents, we synthesized 12 novel chlorine‐substituted sulfonyl hydrazone compounds containing aryl sulfonate ester groups. These compounds were evaluated for their inhibitory effects on AChE, hCA I, and hCA II enzymes. The synthesized compounds exhibited low nanomolar inhibitory activity, with K i values ranging from 9.58 ± 2.22 to 104.04 ± 23.82 nM for AChE, 9.12 ± 2.21 to 477.63 ± 218.52 nM for hCA I, and 17.54 ± 7.74 to 564.62 ± 213.98 nM for hCA II. Notably, compound 6 showed strong inhibitory activity against hCA I ( K i = 9.12 ± 2.21 nM; acetazolamide (AZA) = 26.54 ± 3.11 nM) and hCA II ( K i = 17.54 ± 7.74 nM; AZA = 21.73 ± 2.42 nM), whereas compound 4 exhibited superior AChE inhibition ( K i = 9.58 ± 2.22 nM; TAC = 23.12 ± 2.05 nM). The chemical structures of the synthesized compounds were characterized using advanced spectroscopic techniques, including FT‐IR, 1 H‐NMR, and 13 C‐NMR spectroscopy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Science, Department of Chemistry, Atatürk University, Erzurum, Turkey.
- Siran Dursun Keles Vocational School of Health Services, Gümüshane University, Gümüshane, Turkey.
- East Anatolian High Technology Application and Research Center, Atatürk University, Erzurum, Turkey.
- Kars Vocational School, Department of Material and Material Processing Technologies, Kafkas University, Kars, Turkey.
ORCID-Profile: Erbay Kalay
Zitieren
APA
Öztürk, C., Balci, N., Aslan, O. N., & Kalay, E. (2025). Novel Sulfonylhydrazones With Sulfonate Ester Framework: Promising Dual Inhibitors of AChE and hCAs. Biotechnology and Applied Biochemistry, 72(6), 1752-1762. https://doi.org/10.1002/bab.2780
Vancouver
Öztürk C, Balci N, Aslan ON, Kalay E. Novel Sulfonylhydrazones With Sulfonate Ester Framework: Promising Dual Inhibitors of AChE and hCAs. Biotechnology and Applied Biochemistry. 2025;72(6):1752-1762. doi:10.1002/bab.2780
BibTeX
@article{ztrk2025,
author = {Öztürk, Cansu and Balci, Neslihan and Aslan, Osman Nuri and Kalay, Erbay},
title = {Novel Sulfonylhydrazones With Sulfonate Ester Framework: Promising Dual Inhibitors of AChE and hCAs},
journal = {Biotechnology and Applied Biochemistry},
year = {2025},
volume = {72},
number = {6},
pages = {1752--1762},
doi = {10.1002/bab.2780}
}
EUVIMED